CCHE Seminar Series: How industry supports innovation in drug reimbursement decision-making in Canada
How industry supports innovation in drug reimbursement decision-making in Canada
October 20, 2023, 10am-12pm, HS Room 412 and Zoom
Abstract: The contribution of industry to drug reimbursement decision-making in Canada extends beyond the submission of health technology assessment (HTA) submissions. Cal will provide an overview of what industry health economics and market access professionals do on a day-to-day basis as well as give an overview of the further work they do in terms of spurring innovation in drug reimbursement decision-making. Such activities include: the design and execution of real-world evidence studies, working with key stakeholders such as patient groups, and advocating for policy change to ensure that current methods used to evaluate new health technologies are fit-for-purpose with recent examples such as the “Championing Oncology Relevant Endpoints (CORE) in Canada” initiative.
Cal is a Senior Manager for Market Access Strategy & Health Economics at AstraZeneca Canada where he has been since November 2020. Cal has more than 10 years of experience working in market access and health economics. Prior to joining AstraZeneca, Cal was a Lead in Health Economics at the Canadian Agency for Drugs and Technologies in Health (CADTH) and before that worked for many years in consultancy. Cal has an MSc in Health Economics from City, University of London, UK.PDFCCHE-Cal-Shephard...